• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Kaurane diterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpenoids Kaurane diterpenoids

Research Brief on Kaurane-7,16,17-triol,17-(benzeneacetate), (7b)- (CAS: 1169806-00-1): Recent Advances and Applications

Kaurane-7,16,17-triol,17-(benzeneacetate), (7b)- (CAS: 1169806-00-1) is a diterpenoid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activities, and potential clinical applications. The compound belongs to the kaurane diterpenoid family, which is known for its diverse pharmacological properties, including anti-inflammatory, anti-cancer, and neuroprotective effects.

Recent studies have highlighted the synthetic pathways for Kaurane-7,16,17-triol,17-(benzeneacetate), (7b)-, emphasizing the use of advanced catalytic methods to achieve high yields and enantiomeric purity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel enzymatic approach to synthesize this compound, which significantly reduced the number of steps required compared to traditional chemical synthesis. This advancement not only improves the scalability of production but also enhances the sustainability of the process, aligning with the growing demand for green chemistry in pharmaceutical manufacturing.

The biological activities of Kaurane-7,16,17-triol,17-(benzeneacetate), (7b)- have been extensively investigated in preclinical models. A key finding from a 2022 study in Bioorganic & Medicinal Chemistry Letters revealed its potent anti-inflammatory effects, mediated through the inhibition of NF-κB signaling pathways. This mechanism suggests potential applications in treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Additionally, the compound has shown promising anti-cancer activity in vitro, particularly against breast and lung cancer cell lines, by inducing apoptosis and inhibiting angiogenesis.

Further research has explored the neuroprotective properties of Kaurane-7,16,17-triol,17-(benzeneacetate), (7b)-. A 2023 study in Neuropharmacology reported that the compound could mitigate oxidative stress and neuronal apoptosis in models of Parkinson’s disease, suggesting its potential as a therapeutic agent for neurodegenerative disorders. These findings are particularly significant given the limited treatment options currently available for such conditions.

Despite these promising results, challenges remain in the clinical translation of Kaurane-7,16,17-triol,17-(benzeneacetate), (7b)-. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through further pharmacokinetic and pharmacodynamic studies. Recent efforts have focused on structural modifications to enhance its drug-like properties, as highlighted in a 2023 review in Expert Opinion on Drug Discovery.

In conclusion, Kaurane-7,16,17-triol,17-(benzeneacetate), (7b)- (CAS: 1169806-00-1) represents a promising candidate for drug development, with demonstrated efficacy in preclinical models of inflammation, cancer, and neurodegeneration. Future research should prioritize optimizing its pharmacokinetic profile and conducting rigorous clinical trials to validate its therapeutic potential. The continued exploration of this compound underscores the importance of diterpenoids in modern drug discovery and their potential to address unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)